BusinessApellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with EculizumabBy Nasdaq OMXApr 16, 2018, 1:23 PM UTC
BusinessAchillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor DBy Nasdaq OMXDec 20, 2017, 11:05 AM UTC
BusinessAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical ProgramsBy Nasdaq OMXNov 1, 2017, 8:06 PM UTC
BusinessUSPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D InhibitorBy Nasdaq OMXOct 24, 2017, 10:05 AM UTC
BusinessAkari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceBy Nasdaq OMXSep 19, 2017, 11:00 AM UTC
BusinessAchillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D InhibitorBy Nasdaq OMXAug 8, 2017, 8:02 PM UTC
BusinessAchillion to Present at the 2017 JMP Securities Life Sciences ConferenceBy Nasdaq OMXJun 15, 2017, 8:05 PM UTC
